DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.

Publication/Presentation Date

1-1-2020

Abstract

We lack tools to risk-stratify triple-negative breast cancer (TNBC). Our goal was to develop molecular tools to predict disease recurrence. Methylation array analysis was performed on 110 samples treated by locoregional therapy obtained from institutional cohorts. Discovered marker sets were then tested by Kaplan-Meier analyses in a prospectively collected TNBC cohort of 49 samples from the no-chemotherapy arms of IBCSG trials VIII and IX, and by logistic regression in a chemotherapy-treated cohort of 121 TNBCs from combined IBCSG trials and institutional repositories. High methylation was associated with shorter recurrence-free interval in the no-chemotherapy arm of the IBCSG studies, as well as in the chemotherapy-treated patients within the combined institutional and IBCSG chemotherapy cohorts (100 marker panel,

Volume

6

First Page

3

Last Page

3

ISSN

2374-4677

Disciplines

Medicine and Health Sciences

PubMedID

32025567

Department(s)

Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology Residents, Fellows and Residents

Document Type

Article

Share

COinS